News

e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH
LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will present ...
Le Lézard42m
Major Study Shows Liver Health Measured with cT1 Predicts Clinical Outcomes
Nature Medicine today published a study showing that Perspectum's iron corrected T1, or cT1, predicts liver-related and cardiac outcomes, including morbidity. Liver disease is a modifiable cardiac ...
e-therapeutics plc: e-therapeutics Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH
LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will present ...
Rheumatology Advisor59m
Semaglutide Beneficial in Metabolic Dysfunction-Associated Steatohepatitis, Fibrosis
For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.